Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Dow
Mallinckrodt
Cipla
US Department of Justice
US Army
Chinese Patent Office
Medtronic
Argus Health

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,406,715

« Back to Dashboard

Summary for Patent: 6,406,715
Title: Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
Abstract:Intermediate release nicotinic acid formulations having unique urinary metabolite profiles, which are suitable for oral administration once-a-day as a single dose during a 24 hour period for treating hyperlipidemia without causing drug-induced hepatotoxicity or drug-induced elevations in uric acid or glucose or both to levels that require the therapy to be discontinued, are disclosed.
Inventor(s): Cefali; Eugenio A. (Lauderhill, FL)
Assignee: Kos Pharmaceuticals, Inc. (Miami, FL)
Application Number:08/962,423
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,406,715
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,406,715

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,406,715

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 289197 ➤ Try a Free Trial
Australia 4751802 ➤ Try a Free Trial
Australia 6348198 ➤ Try a Free Trial
Australia 6454598 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Moodys
Deloitte
QuintilesIMS
Chinese Patent Office
US Department of Justice
Cantor Fitzgerald
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.